Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Human retinoic acid–regulated CD161+ regulatory T cells support wound repair in intestinal mucosa


Repair of tissue damaged during inflammatory processes is key to the return of local homeostasis and restoration of epithelial integrity. Here we describe CD161+ regulatory T (Treg) cells as a distinct, highly suppressive population of Treg cells that mediate wound healing. These Treg cells were enriched in intestinal lamina propria, particularly in Crohn’s disease. CD161+ Treg cells had an all-trans retinoic acid (ATRA)-regulated gene signature, and CD161 expression on Treg cells was induced by ATRA, which directly regulated the CD161 gene. CD161 was co-stimulatory, and ligation with the T cell antigen receptor induced cytokines that accelerated the wound healing of intestinal epithelial cells. We identified a transcription-factor network, including BACH2, RORγt, FOSL2, AP-1 and RUNX1, that controlled expression of the wound-healing program, and found a CD161+ Treg cell signature in Crohn’s disease mucosa associated with reduced inflammation. These findings identify CD161+ Treg cells as a population involved in controlling the balance between inflammation and epithelial barrier healing in the gut.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: CD161+ Treg cells are a discrete population of memory Treg cells.
Fig. 2: CD161+ Treg cells have classical features of bona fide Treg cells.
Fig. 3: CD161 expression is regulated by retinoic acid.
Fig. 4: CD161+ Treg cells are regulatory both in vitro and in vivo.
Fig. 5: CD161 ligation is co-stimulatory and induces cytokine production from CD161+ Treg cells.
Fig. 6: Genome-wide chromatin landscapes define the regulatory circuitry of CD161+ Treg cells.
Fig. 7: CD161+ Treg cells accelerate wound healing and are associated with lower inflammation in IBD.

Data availability

The data generated for this study have been deposited at the Gene Expression Omnibus (GEO) under accession code GSE119375.


  1. 1.

    Edozie, F. C. et al. Regulatory T-cell therapy in the induction of transplant tolerance: the issue of subpopulations. Transplantation 98, 370–379 (2014).

    CAS  Article  Google Scholar 

  2. 2.

    Sakaguchi, S., Wing, K., Onishi, Y., Prieto-Martin, P. & Yamaguchi, T. Regulatory T cells: How do they suppress immune responses? Int. Immunol. 21, 1105–1111 (2009).

    CAS  Article  Google Scholar 

  3. 3.

    Roychoudhuri, R. et al. BACH2 represses effector programs to stabilize Treg-mediated immune homeostasis. Nature 498, 506–510 (2013).

    CAS  Article  Google Scholar 

  4. 4.

    Yadav, M. et al. Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J. Exp. Med. 209, 1713–1722 (2012).

    CAS  Article  Google Scholar 

  5. 5.

    Thornton, A. M. et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J. Immunol. 184, 3433–3441 (2010).

    CAS  Article  Google Scholar 

  6. 6.

    Floess, S. et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol. 5, e38 (2007).

    Article  Google Scholar 

  7. 7.

    Ohkura, N. et al. T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development. Immunity 37, 785–799 (2012).

    CAS  Article  Google Scholar 

  8. 8.

    Polansky, J. K. et al. DNA methylation controls Foxp3 gene expression. Eur. J. Immunol. 38, 1654–1663 (2008).

    CAS  Article  Google Scholar 

  9. 9.

    Shih, H.-Y. et al. Transcriptional and epigenetic networks of helper T and innate lymphoid cells. Immunol. Rev. 261, 23–49 (2014).

    CAS  Article  Google Scholar 

  10. 10.

    Oldenhove, G. et al. Decrease of Foxp3+ Treg cell number and acquisition of effector cell phenotype during lethal infection. Immunity 31, 772–786 (2009).

    CAS  Article  Google Scholar 

  11. 11.

    Chaudhry, A. et al. CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. Science 326, 986–991 (2009).

    CAS  Article  Google Scholar 

  12. 12.

    Zheng, Y. et al. Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control TH2 responses. Nature 458, 351–356 (2009).

    CAS  Article  Google Scholar 

  13. 13.

    Koch, M. A. et al. The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat. Immunol. 10, 595–602 (2009).

    CAS  Article  Google Scholar 

  14. 14.

    Wohlfert, E. A. et al. GATA3 controls Foxp3+ regulatory T cell fate during inflammation in mice. J. Clin. Invest. 121, 4503–4515 (2011).

    CAS  Article  Google Scholar 

  15. 15.

    Yu, F., Sharma, S., Edwards, J., Feigenbaum, L. & Zhu, J. Dynamic expression of transcription factors T-bet and GATA-3 by regulatory T cells maintains immunotolerance. Nat. Immunol. 16, 197–206 (2015).

    CAS  Article  Google Scholar 

  16. 16.

    Kordasti, S. et al. Deep phenotyping of Tregs identifies an immune signature for idiopathic aplastic anemia and predicts response to treatment. Blood 128, 1193–1205 (2016).

    CAS  Article  Google Scholar 

  17. 17.

    Miyara, M. et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30, 899–911 (2009).

    CAS  Article  Google Scholar 

  18. 18.

    Booth, N. J. et al. Different proliferative potential and migratory characteristics of human CD4+ regulatory T cells that express either CD45RA or CD45RO. J. Immunol. 184, 4317–4326 (2010).

    CAS  Article  Google Scholar 

  19. 19.

    Maloy, K. J. & Powrie, F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 474, 298–306 (2011).

    CAS  Article  Google Scholar 

  20. 20.

    Povoleri, G. A. M. et al. Thymic versus induced regulatory T cells—Who regulates the regulators. Front. Immunol. 4, 169 (2013).

    CAS  Article  Google Scholar 

  21. 21.

    Maloy, K. J. et al. CD4+CD25+ T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms. J. Exp. Med. 197, 111–119 (2003).

    CAS  Article  Google Scholar 

  22. 22.

    Maul, J. et al. Peripheral and intestinal regulatory CD4+CD25(high) T cells in inflammatory bowel disease. Gastroenterology 128, 1868–1878 (2005).

    CAS  Article  Google Scholar 

  23. 23.

    Afzali, B. et al. CD161 expression characterizes a subpopulation of human regulatory T cells that produces IL-17 in a STAT3-dependent manner. Eur. J. Immunol. 43, 2043–2054 (2013).

    CAS  Article  Google Scholar 

  24. 24.

    Lanier, L. L., Chang, C. & Phillips, J. H. Human NKR-P1A. A disulfide-linked homodimer of the C-type lectin superfamily expressed by a subset of NK and T lymphocytes. J. Immunol. 153, 2417–2428 (1994).

    CAS  PubMed  Google Scholar 

  25. 25.

    Fergusson, J. R. et al. CD161 defines a transcriptional and functional phenotype across distinct human T cell lineages. Cell Rep. 9, 1075–1088 (2014).

    CAS  Article  Google Scholar 

  26. 26.

    Cosmi, L. et al. Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor. J. Exp. Med. 205, 1903–1916 (2008).

    CAS  Article  Google Scholar 

  27. 27.

    Germain, C. et al. Induction of lectin-like transcript 1 (LLT1) protein cell surface expression by pathogens and interferon-γ contributes to modulate immune responses. J. Biol. Chem. 286, 37964–37975 (2011).

    CAS  Article  Google Scholar 

  28. 28.

    Wolfkamp, S. C. S. et al. Single nucleotide polymorphisms in C-type lectin genes, clustered in the IBD2 and IBD6 susceptibility loci, may play a role in the pathogenesis of inflammatory bowel diseases. Eur. J. Gastroenterol. Hepatol. 24, 965–970 (2012).

    CAS  Article  Google Scholar 

  29. 29.

    Diggins, K. E., Ferrell, P. B. & Irish, J. M. Methods for discovery and characterization of cell subsets in high dimensional mass cytometry data. Methods 82, 55–63 (2015).

    CAS  Article  Google Scholar 

  30. 30.

    Qiu, P. et al. Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE. Nat. Biotechnol. 29, 886–891 (2011).

    CAS  Article  Google Scholar 

  31. 31.

    Thomas, S. Y. et al. CD1d-restricted NKT cells express a chemokine receptor profile indicative of Th1-type inflammatory homing cells. J. Immunol. 171, 2571–2580 (2003).

    CAS  Article  Google Scholar 

  32. 32.

    Venturi, V. et al. Method for assessing the similarity between subsets of the T cell receptor repertoire. J. Immunol. Methods 329, 67–80 (2008).

    CAS  Article  Google Scholar 

  33. 33.

    Ferraro, A. et al. Interindividual variation in human T regulatory cells. Proc. Natl Acad. Sci. USA 111, E1111–E1120 (2014).

    CAS  Article  Google Scholar 

  34. 34.

    Kim, Y. C. et al. Oligodeoxynucleotides stabilize Helios-expressing Foxp3+ human T regulatory cells during in vitro expansion. Blood 119, 2810–2818 (2012).

    CAS  Article  Google Scholar 

  35. 35.

    Scotta, C. et al. Differential effects of rapamycin and retinoic acid on expansion, stability and suppressive qualities of human CD4+CD25+FOXP3+ T regulatory cell subpopulations. Haematologica 98, 1291–1299 (2013).

    CAS  Article  Google Scholar 

  36. 36.

    Afzali, B. et al. Comparison of regulatory T cells in hemodialysis patients and healthy controls: implications for cell therapy in transplantation. Clin. J. Am. Soc. Nephrol. 8, 1396–1405 (2013).

    CAS  Article  Google Scholar 

  37. 37.

    Thornton, A. M. & Shevach, E. M. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188, 287–296 (1998).

    CAS  Article  Google Scholar 

  38. 38.

    Cao, X. et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 27, 635–646 (2007).

    CAS  Article  Google Scholar 

  39. 39.

    Rosen, D. B. et al. Functional consequences of interactions between human NKR-P1A and its ligand LLT1 expressed on activated dendritic cells and B cells. J. Immunol. 180, 6508–6517 (2008).

    CAS  Article  Google Scholar 

  40. 40.

    Kitoh, A. et al. Indispensable role of the Runx1-Cbfβ transcription complex for in vivo-suppressive function of FoxP3+ regulatory T cells. Immunity 31, 609–620 (2009).

    CAS  Article  Google Scholar 

  41. 41.

    Ciofani, M. et al. A validated regulatory network for Th17 cell specification. Cell 151, 289–303 (2012).

    CAS  Article  Google Scholar 

  42. 42.

    Afzali, B. et al. BACH2 immunodeficiency illustrates an association between super-enhancers and haploinsufficiency. Nat. Immunol. 18, 813–823 (2017).

    CAS  Article  Google Scholar 

  43. 43.

    Hong, S. N. et al. RNA-seq reveals transcriptomic differences in inflamed and noninflamed intestinal mucosa of Crohn’s disease patients compared with normal mucosa of healthy controls. Inflamm. Bowel Dis. 23, 1098–1108 (2017).

    Article  Google Scholar 

  44. 44.

    Sefik, E. et al. Individual intestinal symbionts induce a distinct population of RORγ+ regulatory T cells. Science 349, 993–997 (2015).

    CAS  Article  Google Scholar 

  45. 45.

    Kim, B.-S. et al. Generation of RORγt+ antigen-specific T regulatory 17 cells from Foxp3+ precursors in autoimmunity. Cell Rep. 21, 195–207 (2017).

    CAS  Article  Google Scholar 

  46. 46.

    Hovhannisyan, Z., Treatman, J., Littman, D. R. & Mayer, L. Characterization of interleukin-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases. Gastroenterology 140, 957–965 (2011).

    CAS  Article  Google Scholar 

  47. 47.

    Blatner, N. R. et al. Expression of RORγt marks a pathogenic regulatory T cell subset in human colon cancer. Sci. Trans. Med. 4, 164ra159 (2012).

    Article  Google Scholar 

  48. 48.

    Komatsu, N. et al. Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat. Med. 20, 62–68 (2014).

    CAS  Article  Google Scholar 

  49. 49.

    Yang, B.-H. et al. Foxp3+ T cells expressing RORγt represent a stable regulatory T-cell effector lineage with enhanced suppressive capacity during intestinal inflammation. Mucosal Immunol 9, 444–457 (2016).

    CAS  Article  Google Scholar 

  50. 50.

    Nosbaum, A. et al. Cutting edge: regulatory T cells facilitate cutaneous wound healing. J. Immunol. 196, 2010–2014 (2016).

    CAS  Article  Google Scholar 

  51. 51.

    O’Connor, W. et al. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat. Immunol. 10, 603–609 (2009).

    Article  Google Scholar 

  52. 52.

    Hueber, W. et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61, 1693–1700 (2012).

    CAS  Article  Google Scholar 

  53. 53.

    Lindemans, C. A. et al. Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration. Nature 528, 560–564 (2015).

    CAS  Article  Google Scholar 

  54. 54.

    Zenewicz, L. A. et al. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 29, 947–957 (2008).

    CAS  Article  Google Scholar 

  55. 55.

    Amir, E.-A. D. et al. viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. Nat. Biotechnol. 31, 545–552 (2013).

    CAS  Article  Google Scholar 

  56. 56.

    Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).

    CAS  Article  Google Scholar 

  57. 57.

    Barrientos, S., Stojadinovic, O., Golinko, M. S., Brem, H. & Tomic-Canic, M. Growth factors and cytokines in wound healing. Wound Repair Regen. 16, 585–601 (2008).

    Article  Google Scholar 

  58. 58.

    Deonarine, K. et al. Gene expression profiling of cutaneous wound healing. J. Transl. Med. 5, 11 (2007).

    Article  Google Scholar 

  59. 59.

    Peake, M. A. et al. Identification of a transcriptional signature for the wound healing continuum. Wound Repair Regen. 22, 399–405 (2014).

    Article  Google Scholar 

  60. 60.

    Zheng, G. X. Y. et al. Massively parallel digital transcriptional profiling of single cells. Nat. Commun. 8, 14049 (2017).

    CAS  Article  Google Scholar 

  61. 61.

    Gong, W., Kwak, I.-Y., Pota, P., Koyano-Nakagawa, N. & Garry, D. J. DrImpute: imputing dropout events in single cell RNA sequencing data. BMC Bioinformatics 19, 220 (2018).

    Article  Google Scholar 

  62. 62.

    Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411–420 (2018).

    CAS  Article  Google Scholar 

  63. 63.

    Zheng, Y. et al. Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature 463, 808–812 (2010).

    CAS  Article  Google Scholar 

  64. 64.

    Robins, H. S. et al. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood 114, 4099–4107 (2009).

    CAS  Article  Google Scholar 

  65. 65.

    Carlson, C. S. et al. Using synthetic templates to design an unbiased multiplex PCR assay. Nat. Commun. 4, 2680 (2013).

    Article  Google Scholar 

  66. 66.

    Mathelier, A. et al. JASPAR 2016: a major expansion and update of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 44, D110–D115 (2016).

    CAS  Article  Google Scholar 

  67. 67.

    Rovedatti, L. et al. Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut 58, 1629–1636 (2009).

    CAS  Article  Google Scholar 

  68. 68.

    Cooke, K. R. et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood 88, 3230–3239 (1996).

    CAS  PubMed  Google Scholar 

  69. 69.

    Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y. & Greenleaf, W. J. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat. Methods 10, 1213–1218 (2013).

    CAS  Article  Google Scholar 

  70. 70.

    Shih, H.-Y. et al. Developmental acquisition of regulomes underlies innate lymphoid cell functionality. Cell 165, 1120–1133 (2016).

    CAS  Article  Google Scholar 

  71. 71.

    Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357–359 (2012).

    CAS  Article  Google Scholar 

  72. 72.

    Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38, 576–589 (2010).

    CAS  Article  Google Scholar 

  73. 73.

    Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26, 841–842 (2010).

    CAS  Article  Google Scholar 

  74. 74.

    Ye, T. et al. seqMINER: an integrated ChIP-seq data interpretation platform. Nucleic Acids Res. 39, e35 (2011).

    CAS  Article  Google Scholar 

  75. 75.

    Häsler, R. et al. Uncoupling of mucosal gene regulation, mRNA splicing and adherent microbiota signatures in inflammatory bowel disease. Gut 66, 2087–2097 (2016).

    Article  Google Scholar 

Download references


The authors thank patients who contributed samples toward this study. This work was supported by the Wellcome Trust (grant 097261/Z/11/Z to B.A. and WT101159 to N.P.), the Crohn’s and Colitis Foundation of America (grant CCFA no. 3765 — CCFA genetics initiative to A.L.), British Heart Foundation (grant RG/13/12/30395 to G.L.), institutional start-up fund from Purdue University and National Heart, Lung, and Blood Institute (grant 5K22HL125593-02 to M.K.). Research was also supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at Guy’s and St Thomas’ National Health Service (NHS) Foundation Trust and King’s College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. This research was supported (in part) by the Intramural Research Programs of the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the National Institute of Diabetes and Digestive and Kidney Diseases and the National Heart, Lung, and Blood Institute of the National Institutes of Health. The authors thank J. O’Shea (National Institutes of Health) for his support and for providing access to ATAC-seq, the National Heart, Lung, and Blood Institute DNA Sequencing and Genomics Core for performing single-cell sequencing experiment and acknowledge the assistance of M. Arno (Genomics Centre, King’s College London) with gene expression microarray studies as well as S. Heck and R. Ellis (Biomedical Research Centre Flow Core Facility, King’s College London) for CyTOF data acquisition. In addition, the authors thank E. Mathé (Ohio State University) for critically reading the manuscript.

Author information




G.A.M.P. designed and performed experiments, analyzed data and wrote the manuscript. N.C., N.P. and P.P. provided patient samples and clinical and scientific input. S.K. designed the CyTOF panel, analyzed and interpreted data, provided scientific input and wrote the paper. M.K. analyzed and interpreted genomics data, provided scientific input and wrote the paper. G.L. provided scientific input, supervised the project and wrote the manuscript. B.A. conceptualized the study, supervised the project, analyzed data and wrote the manuscript. E.N.-L., C.S., G.F., Y.-C.C., P.B., D.B., B.C., M.R., R.M., E.P., D.Chauss, H.-W.S., H.-Y.S., D.Cousins, C.K., M.P. and A.L. performed experiments, analyzed data and/or provided scientific input.

Corresponding author

Correspondence to Behdad Afzali.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Integrated supplementary information

Supplementary Figure 1 CD161+ Treg cells are a discrete population of memory Treg cells.

(a) Heat map showing signal intensity of selected markers for each node of the populations shown in Fig. 1c. (b–e) Clustering of populations of Tconv and Treg cells by single-cell RNA-seq (scRNAseq) showing the tSNE plot of 2,636 cells from n= 3 independent donors separated into six major (clusters 0–6) and two minor (clusters 7 and 8) clusters (b), feature plots showing expression of three Treg markers (IL2RA encoding CD25, IL7R encoding CD127 and FOXP3 encoding FOXP3), KLRB1 (encoding CD161) and two naive/memory markers (SELL encoding CD62L and CCR7 encoding CCR7) (c), a heat map showing the top 20 discriminatory genes per cluster with representative genes of each cluster indicated (d) and population clustering (e) based on expression of the transcripts shown in c. Clusters in b are color-coded and labeled according to expression of the markers shown in e. (f) Clustering of Tconv and Treg subpopulations using protein expression data sourced from CyTOF in Fig. 1a incorporating the same markers as in e and also including CD45RA and CD45RO. Clustering of subpopulations in f is similar to that from scRNAseq (e). (g,h) viSNE plots (g) and 2D minimum spanning tree (h) of CD4+ T cells clustered following staining with anti-CD4, anti-CD25, anti-CD127, anti-CD45RA and anti-CD161 for flow cytometry. Shown in g are heat maps for expression of the indicated markers, with an arrow indicating CD161 expression in Treg cells. Node size in h represents cell number and color CD161 median intensity. Grouped together are naive (circled in orange), memory (circled in yellow) and CD161+ (circled in purple) Treg cells, as well as populations of naive (circled in black), memory (circled in black) and CD161+ (circled in red) Tconv cells. The data in g and h are representative of n = 4 experiments. *P < 0.01, **P < 0.001, ***P < 0.0001 by one-way ANOVA.

Supplementary Figure 2 CD161+ Treg cells are distinct from other CD161-expressing T cells.

(a) Representative example of the FACS sorting strategy for naive (orange), memory (yellow) and CD161+ (purple) Treg cells. (b) Proportions of each Treg subpopulation in healthy human donor peripheral blood (cumulative data from n = 10 donors); bars show mean + s.e.m. (c) Representative (top) and cumulative (bottom) expression of TCR Vα24-Jα18 and Vα7.2 in total CD4+ T cells and CD161+ Treg cells. Both cell types show minimal expression of these invariant TCR chains. Data are from n = 3 independent experiments. (d) Contribution of the three highest (BV05, BV06 and BV07) and one of the lowest (BV19) TCRBV families to the overall TCR repertoire in naive, memory and CD161+ Treg cells as well as CD161+ and total Tconv cells. Data are from n = 3 independent experiments; bars show mean + s.e.m. (e) Average percentage of TCR sequences either unique or shared among naive, memory and CD161+ Treg cells, CD161+ and total Tconv cells (cumulative data from n = 3 experiments). *P < 0.01, **P < 0.001, ***P < 0.0001 by one-way ANOVA.

Supplementary Figure 3 Transcriptome and methylome of CD161+ Treg cells.

(a) Principal-component analysis (PCA) 2D mapping of variance in expression of transcripts in freshly isolated naive, memory and CD161+ Treg cells (n = 3). (b–d) Scatterplots showing correlation between mean gene expression of freshly isolated Treg subpopulations (n = 3). (e,f) GSEA plots for core human Treg signature genes comparing freshly isolated naive to memory Treg cells (e) and to CD161+ Tregs cells (f) (n = 3 per group). NES, normalized enrichment score; empirical P and multiple-test adjusted q values from GSEA are shown. (g) Schematic representation of FOXP3, IL2RA and CTLA4 gene loci showing the target sequence and conserved CpGs assayed for methylation analysis in Fig. 2e. (h) Mean region methylation percentage of FOXP3 TSDR, IL2RA and CTLA4 loci from three male donors. Data are from n = 3 independent experiments; bars show mean + s.e.m. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 by one-way ANOVA.

Supplementary Figure 4 Regulation of CD161 by retinoic acid.

(a) Heat map of leading edge (core enriched) genes from GSEA for ATRA-regulated genes comparing freshly isolated memory to CD161+ Treg cells (Fig. 3a). Data are from n = 3 independent experiments. (b) CCR9 surface protein expression on memory and CD161+ Treg cells; shown are representative flow cytometry plots (left) and cumulative data from n = 3 independent experiments (right). (c) CD161 expression on Treg cells co-cultured for 5 d with DCs with and without BMS493 at increasing concentrations. Shown are representative plots (left) and cumulative data (right) from n = 3 independent experiments. (d,e) Sequence logo for RARA DNA motif (d) and schematic representation of the KLRB1 and CCR9 gene loci (±5 kb) showing the predicted binding sites of RARA (e); the red arrowhead indicates the binding site for CCR9 selected for analysis in ChIP–qPCR. Bars show mean + s.e.m. throughout the figure. *P < 0.05 by paired t-test.

Supplementary Figure 5 CD161+ Treg cells are highly regulatory.

(a,b) Cumulative mean percentage suppressive function of freshly isolated naive, memory and CD161+ Treg cells from Fig. 4a (n = 4 experiments) (a) and representative IC50 value calculation (b; dashed arrows show the IC50 for CD161+ and memory Treg cells). (c) Cumulative mean percentage suppressive function of memory and CD161+ Treg cells after in vitro expansion for 2 weeks (n = 4 experiments). (d) Suppression of Tconv cell proliferation when in direct contact with Treg cells or when separated by a Transwell at a Treg:Tconv ratio of 1:1 (cumulative data from n = 4 independent experiments). (e) Suppressive function of Treg cells under neutral (null) conditions or in the presence of blocking antibodies directed against CD161, PDL1, TGFβRII or IL10R, all at a Treg:Tconv ratio of 1:2 (cumulative data from n = 3 independent experiments). (f) Suppressive function of CD161+ Treg cells under neutral (null) conditions or in the presence of TH1 and TH17 skewing conditions, all at a Treg:Tconv ratio of 1:2 (cumulative data from n = 3 independent experiments). (g) Expression of perforin, granzyme A and B in subpopulations of Treg cells, with NK cells as a positive control; shown are representative flow cytometry plots for each marker (left) and cumulative data from n = 3 independent experiments (right). Bar charts show mean + s.e.m. throughout the figure. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by two-way ANOVA (a–e) and one-way ANOVA (g).

Supplementary Figure 6 CD161+ Treg cells produce multiple cytokines upon activation.

(a) Differentially expressed genes (at least twofold change at P < 0.05) following 4 h of stimulation of memory and naive Treg cells with anti-CD3/CD28. (b) Volcano plot showing significant genes differentially expressed in CD161+ Treg cells after 4 h of activation with anti-CD3/CD28. Differentially expressed genes are shown in blue; red indicates significantly upregulated cytokine genes that are differentially expressed compared to memory Treg cells (see Fig. 5c); orange indicates other cytokine genes of interest upregulated in activated CD161+ Treg cells. The data in a are b are from three independent experiments. (c,d) Cell sorting of IL-17+ and IL-17 CD161+ Treg cells by surface IL-17 capture. Shown are representative flow cytometry plots with double staining for intracellular and extracellular (captured on the surface) IL-17 with (right) and without (left) fixation and permeabilization (c) and the sorting strategy using IL-17 surface capture and post-sorting purity for the IL-17+ and IL-17 fractions of CD161+ Treg cells (d). Shown in c and d are representative examples from n = 3 and n = 4 independent experiments, respectively.

Supplementary Figure 7 Global analysis of Treg regulomes.

(a) Open chromatin regions (OCRs) at prototypical Treg gene loci from Fig. 6a. (b) Genomic distribution of ATAC peaks (promoter, intragenic or intergenic regions) in the three groups shown in Fig. 6a. (c) P values (cumulative hypergeometric test P values calculated by Homer) for transcription factor (TF) motifs shown in each cluster in Fig. 6c. Data in ac are from n = 3 experiments. (d) Expression of key TFs participating in gene regulation in CD161+ Treg cells. Shown is the normalized signal intensity (mean + s.e.m.) from n = 3 microarrays for each Treg population. (e) Integrated TF network showing the contribution of each TF to DEGs and overlap between them (fold difference in expression of each TF is also indicated next to the TF). *P < 0.05, **P < 0.01, ***P < 0.001 (Partek analysis of microarrays).

Supplementary Figure 8 CD161+ Treg cells accelerate wound healing.

(a,b) GSEA plots for wound healing–associated genes (a) and wound healing–associated soluble mediators (b) comparing activated CD161+ to memory Treg cells. Data are from n = 3 independent experiments. NES, normalized enrichment score; empirical P and multiple-test-adjusted q values from GSEA are indicated. (c) Wound closure rate of Caco-2 cells cultured in the presence of either medium alone or medium supplemented with culture supernatants (snt) from activated memory or CD161+ Treg cells. Shown are cumulative data from n = 6 independent experiments. (d) Concentration (pg/ml) of stated cytokines in supernatants of CD161+ Treg cells transduced, or not, with control lentivirus or lentivirus encoding BACH2 (cumulative data from n = 6 experiments). Bar charts show mean + s.e.m.; *P < 0.05, **P < 0.01 by one-way ANOVA.

Supplementary information

Supplementary Text and Figures

Supplementary Figures 1–8

Reporting Summary

Supplementary Table 1

List of differentially expressed genes (DEGs)

Supplementary Table 2

Expression of killer cell lectin-like receptors (Klr) in wild-type mouse Treg cells

Supplementary Table 3

Open chromatin regions (OCRs) from ATAC-seq

Supplementary Table 4

Gene lists used for gene set enrichment analyses

Supplementary Table 5

Gene lists used for gene set enrichment analyses

Supplementary Video 1

Wound healing with medium alone. The video shows growth of Caco-2 cells cultured with medium alone. Time-lapse images were recorded from 0–120 h. Shown are representative videos from n = 3 independent experiments

Supplementary Video 2

Wound healing with memory Treg cell supernatants. The video shows growth of Caco-2 cells cultured with medium supplemented with culture supernatants (snt) of activated memory cells. Time-lapse images were recorded from 0–120 h. Shown are representative videos from n = 3 independent experiments

Supplementary Video 3

Wound healing with CD161+ Treg cell supernatants. The video shows growth of Caco-2 cells cultured with medium supplemented with culture supernatants (snt) of CD161+ Treg cells. Time-lapse images were recorded from 0–120 h. Shown are representative videos from n = 3 independent experiments

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Povoleri, G.A.M., Nova-Lamperti, E., Scottà, C. et al. Human retinoic acid–regulated CD161+ regulatory T cells support wound repair in intestinal mucosa. Nat Immunol 19, 1403–1414 (2018).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing